Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis

Journal of the Neurological Sciences

Volumn 373, Issue , 2017, Pages 236-241

  Ferreira, Katerine Panichi Zanin ^a   Oliveira, Sayonara R ^a   Kallaur, Ana Paula ^a   Kaimen Maciel, Damacio R ^a   Lozovoy, Marcell Alysson B ^a   de Almeida, Elaine Regina Delicato ^a   Morimoto, Helena Kaminami ^a   Mezzaroba, Leda ^a   Dichi, Isaias ^a   Reiche, Edna Maria Vissoci ^a   Simão, Andréa Name Colado ^a  

^a UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Disease progression; Ferritin; Hyperferritinemia; Multiple sclerosis; Oxidative stress

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; CARBONYL DERIVATIVE; FERRITIN; IRON; NITRIC OXIDE; TERT BUTYL HYDROPEROXIDE; THIOL GROUP; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HYPERFERRITINEMIA; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; BLOOD; BODY MASS; DISABILITY; LUMINESCENCE; MULTIVARIATE ANALYSIS; PHYSIOLOGY; SMOKING; STATISTICAL MODEL;

ADULT; BIOMARKERS; BODY MASS INDEX; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FERRITINS; HUMANS; IMMUNOLOGIC FACTORS; IRON; LOGISTIC MODELS; LUMINESCENCE; MALE; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; SMOKING;

EID: 85008625981     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2016.12.039     Document Type: Article

References (31)

1. [1] Mahad, D.H., Trapp, B.D., Lassmann, H., Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14 (2015), 183–193.
2. [2] Koch, M., Mostert, J., Arutjunyan, A.V., et al. Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur. J. Neurol. 14 (2007), 529–533.
3. [3] Oliveira, S.R., Kallaur, A.P., Kaimen-Maciel, R., Reiche, E.M.V., Immunopathological mechanisms and oxidative stress damage in multiple sclerosis. Dichi, I., Breganó, J.W., Simão, A.N.C., Cecchini, R., (eds.) Role of Oxidative Stress in Chronic Diseases, 2014, CRC Press, Boca Raton, Fl, 549–588.
4. [4] Sayre, L.M., Perry, G., Smith, M.A., Oxidative stress and neurotoxicity. Chem. Res. Toxicol. 21 (2008), 172–188.
5. [5] Haider, L., Fischer, M.T., Frischer, J.M., et al. Oxidative damage in multiple sclerosis lesions. Brain 134 (2011), 1914–1924.
6. [6] Zandman-Goddard, G., Shoenfeld, Y., Ferritin in autoimmune diseases. Autoimmunity 6 (2007), 457–463.
7. [7] Arosio, P., Levi, S., Ferritin, iron homeostasis, and oxidative damage. Free Radic. Biol. Med. 33 (2002), 457–463.
8. [8] Connor, J.R., Boeshore, K.L., Benkovic, S.A., et al. Isoforms of ferritin have a specific cellular distribution in the brain. J. Neurosci. 37 (1994), 461–465.
9. [9] LeVine, S.M., Lynch, S.G., Ou, C.N., et al. Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res. 821 (1999), 511–515.
10. [10] Sfagos, C., Makes, A.C., Chaidos, A., et al. Serum ferritin, transferrin and soluble transferring receptor levels in multiple sclerosis patients. Mult. Scler. 11 (2005), 272–275.
11. [11] Oliveira, S.R., Kallaur, A.P., Reiche, E.M., et al. Albumin and protein oxidation are predictors that differentiate relapsing-remitting from progressive clinical forms of multiple sclerosis. Mol. Neurobiol., 1-8, 2016.
12. [12] Polman, C.H., Reingold, S.C., Banwell, B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69 (2011), 292–302.
13. [13] Kurtzke, J.F., Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983), 1444–1452.
14. [14] Gonzales-Flecha, B.G., Llesuy, S., Boveris, A., Hydroperoxideinitiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver and muscle. Free Radic. Biol. Med. 10 (1991), 93–100.
15. [15] Witko-Sarsat, V., Friedlander, M., Nguyen Khoa, T., et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J. Immunol. 161 (1998), 2524–2532.
16. [16] Panis, C., Herrera, A.C., Victorino, V.J., et al. Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res. Treat. 133 (2012), 89–97.
17. [17] Hu, M.L., Measurement of protein thiol groups and glutathione in plasma. Abelson, J.N., Simon, M.I., (eds.) Methods Enzymol, 1994, Academic Press, California, 380–382.
18. [18] Repetto, M., Reides, C., Gomez Carretero, M.L., et al. Oxidative stress in blood of HIV infected patients. Clin. Chim. Acta 255 (1996), 107–117.
19. [19] Besler, H.T., Comoglu, S., Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr. Neurosci. 6 (2003), 189–196.
20. [20] Ferretti, G., Bacchetti, T., Principi, F., et al. Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult. Scler. 11 (2005), 677–682.
21. [21] Da Costa, R., Szyper-Kravitz, M., Szekanecz, Z., et al. Ferritin and prolactin levels in multiple sclerosis. Isr. Med. Assoc. J. 13 (2011), 91–95.
22. [22] Hametner, S., Wimmer, I., Haider, L., et al. Iron and neurodegeneration in the multiple sclerosis brain. Ann. Neurol. 74 (2013), 848–861.
23. [23] Zandman-Goddard, G., Shoenfeld, Y., Hyperferritinemia in autoimmunity. Isr. Med. Assoc. J. 10 (2008), 83–84.
24. [24] Rosário, C., Zandman-Goddard, G., Meyron-Holtz, E.G., et al. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 11 (2013), 185–196.
25. [25] Stankiewicz, J., Panter, S.S., Neema, M., et al. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 4 (2007), 371–386.
26. [26] Oliveira, S.R., Kallaur, A.P., Simão, A.N.C., et al. Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J. Neurol. Sci. 321 (2012), 49–53.
27. [27] Ruddell, R.G., Hoang-Le, D., Barwood, J.M., et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 49 (2009), 887–900.
28. [28] Simão, A.N.C., Lozovoy, M.A., Simão, T.N., et al. Immunological and biochemical parameters of patients with metabolic syndrome and the participation of oxidative and nitroactive stress. Braz. J. Med. Biol. Res. 44 (2011), 707–712.
29. [29] Van Meeteren, M.E., Teunissen, C.E., Dijkstra, C.D., et al. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur. J. Clin. Nutr. 59 (2005), 1347–1361.
30. [30] Zhao, G., Arosio, P., Chasteen, N.D., Iron(II) and hydrogen peroxide detoxification by human H-chain ferritin: an EPR spin-trapping study. Biochemistry 45 (2006), 3429–3436.
31. [31] Haider, L., Simeonidou, C., Steinberger, G., et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J. Neurol. Neurosurg. Psychiatry 85 (2014), 1386–1395.